$43.24
+0.12%Aug 25, 2026, 17:00 UTC
Novo Nordisk announced on August 11 that it is rolling out Awiqli, a weekly insulin injection for Type 2 diabetes, the first weekly dose to reach the market after FDA approval in March.
Source:Aug 24, 2026, 17:30 UTC
Roche signed a licensing deal with Hanmi Pharm for HM17321, an obesity drug candidate, paying $190 million upfront with up to $2.3 billion in milestones and royalties, for rights outside South Korea.
Source:Aug 24, 2026, 12:30 UTC
Lexicon Pharmaceuticals earned a $10 million milestone payment from Novo Nordisk after achieving a key Phase 1 development milestone for LX9851, an oral non-incretin obesity candidate being developed by Novo Nordisk.
Source:Aug 20, 2026, 23:59 UTC
Hacker group FulcrumSec leaked 1.2 terabytes of data stolen from Danish pharmaceutical company Novo Nordisk on the open internet on 12 August 2026, following an earlier sample leak on 17 July 2026.
Source:Aug 20, 2026, 11:00 UTC
Celon Pharma announced that its generic semaglutide product Reduzek matched Novo Nordisk's Wegovy and Ozempic in an early-stage bioequivalence study.
Source:Aug 20, 2026, 01:23 UTC
United Laboratories issued a profit warning, expecting net profit of about RMB 340 million for the six months ended June 2026, down about 82% from RMB 1.893 billion a year earlier.
Source:Aug 12, 2026, 22:53 UTC
Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly over its weight-loss drug advertising.
Source:Aug 10, 2026, 12:38 UTC
Novo Nordisk and Amazon Web Services announced a strategic partnership to accelerate drug discovery using AI and cloud technology, including the creation of a joint innovation center in London.
Aug 7, 2026, 07:55 UTC
Novo Nordisk China released its first sustainability case collection and held a launch event in China on August 6, 2026.
Source:Aug 5, 2026, 13:54 UTC
Novo Nordisk's oral semaglutide Rybelsus 14mg received approval in China for a new indication to reduce cardiovascular event risk in high-risk type 2 diabetes patients.
Source:Aug 4, 2026, 13:12 UTC
H1 and Novo Nordisk announced a partnership to scale AI-driven clinical development.
Source:Jul 31, 2026, 17:45 UTC
Pfizer is pursuing a position in the obesity-drug market through its acquisition of Metsera and a broader GLP-1 pipeline.
Source:Jul 31, 2026, 17:24 UTC
BioAge Labs Inc. stock plunged on Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S raised concerns about NLRP3-targeting therapies.
Source:Jul 31, 2026, 15:15 UTC
Novo Nordisk's market capitalization fell by $30.7 billion to $198.5 billion after a failed heart drug trial, a nearly 69% decline from its June 2024 all-time high of $635.7 billion.
Jul 31, 2026, 11:27 UTC
Novo Nordisk announced that its drug Ziltivekimab failed to reduce the risk of major adverse cardiovascular events (MACE) compared to placebo.
Jul 28, 2026, 11:55 UTC
Novo Nordisk achieved a profit margin of 33.1% in the 2026 Fortune Global 500, the highest among pharmaceutical companies.
Source:Jul 24, 2026, 08:33 UTC
Novo Nordisk filed a request in court to preliminarily stop Eli Lilly's allegedly misleading GLP-1 advertising campaign during the litigation.
Jul 21, 2026, 16:15 UTC
Novo Nordisk filed a lawsuit against Eli Lilly in U.S. federal court, accusing Lilly of false advertising in weight-loss drug marketing.
Jul 15, 2026, 10:29 UTC
SOL Group agrees to acquire Danish Novis Medical Co., Ltd.
Source:Jul 14, 2026, 14:42 UTC
Former Akero Therapeutics executives, backed by Fairmount, launch a new publicly traded immunology company centered around a long-acting immunology drug from a Chinese firm.
Source:Jul 2, 2026, 11:39 UTC
Novo Holdings is backing an Italian fund to support drug startups outside Denmark.
Source:Jun 30, 2026, 08:30 UTC
The Trump administration negotiated a monthly $245 price for GLP-1 drugs in Medicare and Medicaid with Eli Lilly and Novo Nordisk, contingent on private Medicare insurers covering the drugs for all uses with a $50 copay.
Source:Jun 29, 2026, 23:59 UTC
York County Council unanimously passed the second reading of a $1.5 billion incentive agreement with a global biopharmaceutical company (Project Palmetto Rock) for a corporate headquarters and manufacturing facility.
Source:Jun 25, 2026, 13:10 UTC
Lexaria Bioscience Corp. began dosing on schedule on June 14, 2026, for its Human Pilot Study #7 (GLP-1-H26-7) evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets.